| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | -0.081 | 0.1 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |